Current and future biomarkers in the treatment of colorectal cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and future biomarkers in the treatment of colorectal cancer
Authors
Keywords
-
Journal
ACTA CLINICA BELGICA
Volume 72, Issue 2, Pages 103-115
Publisher
Informa UK Limited
Online
2016-12-05
DOI
10.1080/17843286.2016.1262996
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Unknown
- (2018) CANCER
- The State of the Art in Colorectal Cancer Molecular Biomarker Testing
- (2016) Raju K. Pillai et al. ADVANCES IN ANATOMIC PATHOLOGY
- Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory
- (2016) A. Sartore-Bianchi et al. ANNALS OF ONCOLOGY
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
- (2016) David Barras et al. CLINICAL CANCER RESEARCH
- Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer
- (2016) Dionisia Quiroga et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study
- (2016) Takeharu Yamanaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring theKRASG13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
- (2016) Eva Segelov et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting HER2: precision oncology for colorectal cancer
- (2016) Hans-Joachim Schmoll LANCET ONCOLOGY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
- (2016) Piero Dalerba et al. NEW ENGLAND JOURNAL OF MEDICINE
- Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
- (2016) R. Moretto et al. ONCOLOGIST
- Molecular pathological classification of colorectal cancer
- (2016) Mike F. Müller et al. VIRCHOWS ARCHIV
- Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas
- (2016) Florence Boissière-Michot et al. VIRCHOWS ARCHIV
- Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances
- (2016) Gustaw Lech WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic impact of mutation profiling in patients with stage II and III colon cancer
- (2016) Yinchen Shen et al. Scientific Reports
- Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review
- (2016) Min Jia et al. Clinical Epigenetics
- Colorectal cancer carcinogenesis: a review of mechanisms
- (2016) Kanwal Tariq et al. Cancer Biology & Medicine
- Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials
- (2016) Lizhen Zhu et al. PLoS One
- Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation
- (2015) Nishi Kothari et al. ACTA ONCOLOGICA
- Unknown
- (2015) CANCER
- Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
- (2015) F. A. Sinicrope et al. CLINICAL CANCER RESEARCH
- A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer
- (2015) Bengt Gustavsson et al. Clinical Colorectal Cancer
- RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data
- (2015) Timothy L. Cannon et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: A p53 Research Group study
- (2015) N. Pilat et al. EJSO
- FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
- (2015) C. Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
- (2015) Frank A. Sinicrope et al. GASTROENTEROLOGY
- Diagnosis and Management of DNA Mismatch Repair-Deficient Colorectal Cancer
- (2015) Zsofia K. Stadler HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC)
- (2015) Sebastian Stintzing et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
- (2015) Rodrigo Dienstmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study
- (2015) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer
- (2015) Margaret M Kozak et al. JOURNAL OF CLINICAL PATHOLOGY
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. JNCI-Journal of the National Cancer Institute
- Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
- (2015) Emanuele Valtorta et al. MODERN PATHOLOGY
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors
- (2015) S. Kopetz et al. ONCOLOGIST
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. JNCI-Journal of the National Cancer Institute
- TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients
- (2015) Daniela Kandioler et al. EBioMedicine
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
- (2014) H. Blons et al. ANNALS OF ONCOLOGY
- Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis
- (2014) Y. Y. Juo et al. ANNALS OF ONCOLOGY
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
- (2014) J. Y. Douillard et al. ANNALS OF ONCOLOGY
- Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
- (2014) E. Missiaglia et al. ANNALS OF ONCOLOGY
- KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
- (2014) H. H. Yoon et al. CLINICAL CANCER RESEARCH
- CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer
- (2014) Stacey Shiovitz et al. GASTROENTEROLOGY
- Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
- (2014) J. C. von Einem et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
- (2014) Lee S. Schwartzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data
- (2014) Antonio F. Di Narzo et al. JNCI-Journal of the National Cancer Institute
- Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
- (2014) Julien Taieb et al. LANCET ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Prospective Multicenter Study of the Impact of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients
- (2014) G. Srivastava et al. ONCOLOGIST
- The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
- (2014) M M Dias et al. PHARMACOGENOMICS JOURNAL
- Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy
- (2014) M K H Maus et al. PHARMACOGENOMICS JOURNAL
- BRAFV600E Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis
- (2014) Dong Chen et al. PLoS One
- Expression of HLA Class I Antigen, Aspirin Use, and Survival After a Diagnosis of Colon Cancer
- (2014) Marlies S. Reimers et al. JAMA Internal Medicine
- Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations
- (2013) Dmitri Mouradov et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) R. Labianca et al. ANNALS OF ONCOLOGY
- Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
- (2013) D J Jonker et al. BRITISH JOURNAL OF CANCER
- Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
- (2013) J M Jürgensmeier et al. BRITISH JOURNAL OF CANCER
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
- (2013) K E Caudle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
- (2013) F. Loupakis et al. EUROPEAN JOURNAL OF CANCER
- Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581
- (2013) Alan P. Venook et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer
- (2013) Enric Domingo et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial
- (2013) Shuji Ogino et al. JNCI-Journal of the National Cancer Institute
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
- (2013) Matthew T Seymour et al. LANCET ONCOLOGY
- Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS
- (2013) Deniz Tural et al. TUMOR BIOLOGY
- Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
- (2012) Tomoya Yokota Anti-Cancer Agents in Medicinal Chemistry
- Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
- (2012) Y. Imamura et al. CLINICAL CANCER RESEARCH
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
- (2012) P. G. Gavin et al. CLINICAL CANCER RESEARCH
- Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
- (2012) X. Liao et al. CLINICAL CANCER RESEARCH
- PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
- (2012) Arjun Sood et al. Clinical Colorectal Cancer
- ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis
- (2012) Trude H Ågesen et al. GUT
- Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
- (2012) Amanda K. Arrington et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer
- (2012) Daniel J. Sargent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer
- (2012) Toshiaki Watanabe et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial
- (2012) Christophe Tournigand et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
- (2012) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
- (2012) A. D. Roth et al. JNCI-Journal of the National Cancer Institute
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer Survival
- (2012) Xiaoyun Liao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
- (2011) Richard D. Kennedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
- (2011) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- (2011) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis
- (2011) Arantza Fariña Sarasqueta et al. CELLULAR ONCOLOGY
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
- (2010) Katsuhiko Nosho et al. JOURNAL OF PATHOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery
- (2010) S. Tejpar et al. ONCOLOGIST
- A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
- (2009) M. Ychou et al. ANNALS OF ONCOLOGY
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets
- (2009) Long Shan Li et al. BRITISH JOURNAL OF PHARMACOLOGY
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
- (2009) H. Prenen et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance and Molecular Associations of 18q Loss of Heterozygosity: A Cohort Study of Microsatellite Stable Colorectal Cancers
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
- (2009) Erika Cecchin et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2009) Bart Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
- (2009) H. I. Hurwitz et al. ONCOLOGIST
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
- (2008) S. Ogino et al. GUT
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon Cancer
- (2008) Yuqiu Jiang et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now